Kazakhstan – According to the research by the World Health Organization, over the past 20 years around the world there has been a clear upward trend in liver diseases. Among the causes of disease there is alcohol abuse, viral infections, side effects of drugs, exposure to toxic chemicals etc. All of these cause cirrhosis of the liver, acute and chronic hepatitis, and cancer, which ranks 5th in the world among all cancers. The most common underlying medical conditions are high blood pressure, hyperlipidemia, diabetes, coronary artery disease. Severe chronic liver diseases are among the ten most common causes of death. Only in the CIS from 500,000 to 1,000,000 people are recorded annually as suffering from one or another liver disease.
Existing drugs that stimulate regeneration and restore liver functions do not fully satisfy the needs of clinical practice. Therefore, search for new highly effective and safe medications remains urgent. The market analysis indicates a large number of drugs, many of which are of synthetic origin and have side effects, and are expensive.
L.N. Gumilyov Eurasian National University researchers have created an inexpensive Kazakh drug based on natural ingredients. The main raw material for them is common weed (spurge), which is popularly called “suttigen”. After studying the chemical composition of plants, scientists have proven its great value. They found in Euphorbia many useful amino acids and trace elements, and were able to get new active substances.
In total, scientists have studied 15 species of milkweed in the search for the most promising. Jungar spurge was selected as a result of the screening. To create the necessary dosage of suttigen substance in powder form ENU scientists used special technology of removal of poisonous milky sap from the milkweed with an extract, while retaining all the medicinal ingredients.
The result of the scientists’ work at the Institute of Bioorganic Chemistry was a new hypoallergenic medication without side effects, which, thanks to its unique composition, has a wide spectrum of action. New hepaprotector “Suttigen” has immune–modeling and antioxidant actions.
Availability of raw materials makes development much cheaper than of their analogues. Thanks to research scientists of the Eurasian National University, Kazakhstan today has a new drug for the treatment of liver diseases, which is available to the public.